Compare AVLN & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVLN | MMI |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2026 | 2013 |
| Metric | AVLN | MMI |
|---|---|---|
| Price | $33.84 | $31.15 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 175.5K | 92.0K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | ★ 84.38 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $719,700,000.00 |
| Revenue This Year | N/A | $14.04 |
| Revenue Next Year | N/A | $11.35 |
| P/E Ratio | ★ N/A | $1,552.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $24.43 |
| 52 Week High | $40.17 | $33.55 |
| Indicator | AVLN | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 44.52 |
| Support Level | $34.22 | $29.69 |
| Resistance Level | $40.08 | $32.34 |
| Average True Range (ATR) | 1.96 | 0.67 |
| MACD | -0.39 | -0.16 |
| Stochastic Oscillator | 9.89 | 15.03 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.